BIOIMPACT CAPITAL LLC
Q2 2024 Form 13-F
BOSTON, MASSACHUSETTS
CIK 0001687078
· CRD 309865
· SEC-registered investment adviser
$643.5M Reported Value Total
SEC Registered
Discretionary Manager
Private funds (Form ADV)
4 funds
· $2.0B gross asset value
Other: $1.8B · Hedge Fund: $138.3M
Source: Form ADV filed 2022-11-17
Reported value
$643.5M
Quarter over quarter
-12.8%
Holdings
44
Top-10 concentration
53.5%
Key People
Form ADV owners & control persons
Christiana Goh Bardon
MANAGING MEMBER
Luke Basil Evnin
MEMBER
Ansbert K Gadicke
MANAGING MEMBER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2024 13F record
Q2 2024 13F filing summary
| Period of report | June 30, 2024 |
|---|---|
| Filed | August 14, 2024 |
| Form | 13F-HR |
| Reported value | $643.5M |
| Positions | 44 |
| Change in reported value | +3.5% |
| New positions | 10 |
| Exited positions | 4 |
| Position turnover | 29.2% |
| Top-10 concentration | 53.5% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
37 | $1.6B |
|
Q1 2026 13F
Filed May 15, 2026
|
41 | $1.3B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
38 | $874.0M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
40 | $610.9M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
44 | $577.2M |
|
Q1 2025 13F
Filed May 15, 2025
|
43 | $581.7M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
47 | $704.4M |
|
Q3 2024 13F
Filed Nov 13, 2024
|
43 | $666.6M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
44 | $643.5M |
|
Q1 2024 13F
Filed May 15, 2024
|
38 | $622.0M |
|
Q4 2023 13F
Filed Feb 13, 2024
|
32 | $427.4M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
32 | $374.6M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
34 | $496.6M |
|
Q1 2023 13F
Filed May 12, 2023
|
31 | $384.9M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
33 | $385.5M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
38 | $422.2M |
|
Q2 2022 13F
Filed Aug 11, 2022
|
37 | $360.0M |
|
Q1 2022 13F
Filed May 13, 2022
|
37 | $372.6M |
|
Q4 2021 13F
Filed Feb 11, 2022
|
33 | $548.5M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
33 | $644.7M |
7 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | CGEM Cullinan Therapeutics, Inc. | $133.4M | 20.73% |
| 2 | INSM Insmed Incorporated | $41.2M | 6.41% |
| 3 | OLMA Olema Pharmaceuticals, Inc. | $28.7M | 4.46% |
| 4 | ITOS iTeos Therapeutics, Inc. | $25.9M | 4.03% |
| 5 | CRNX Crinetics Pharmaceuticals Inc. | $25.0M | 3.88% |
| 6 | MDGL Madrigal Pharmaceuticals inc | $19.9M | 3.1% |
| 7 | IOVA Iovance Biotherapeutics Inc | $19.0M | 2.95% |
| 8 | NTRA Natera Inc | $18.9M | 2.94% |
| 9 | MIRM Mirum Pharmaceuticals Inc | $16.8M | 2.62% |
| 10 | RARE Ultragenyx Pharmaceutical Inc | $15.6M | 2.43% |
| 11 | MLTX Moonlake Immunotherapeutics | $15.1M | 2.35% |
| 12 | GH Guardant Health Inc | $14.4M | 2.24% |
| 13 | IRON Disc Medicine Inc | $13.8M | 2.14% |
| 14 | ALKS Alkermes Plc | $13.4M | 2.09% |
| 15 | EWTX Edgewise Therapeutics Inc | $13.3M | 2.07% |
| 16 | ALXO ALX Oncology Holdings Inc. | $13.2M | 2.04% |
| 17 | MORF MORPHIC HOLDING INC | $12.6M | 1.96% |
| 18 | LNTH Lantheus Holdings Inc | $12.0M | 1.87% |
| 19 | RVMD Revolution Medicines, Inc. | $11.2M | 1.75% |
| 20 | AVDL Avadel Pharmaceuticals PLC | $11.0M | 1.71% |
Values as reported on the Q2 2024 Form 13F. Every position is in the holdings table below.